Tweet
Re: China - 4 cases of H7N9 - Jiangsu province - Updated April 2, 2013
[Source: Business Sohu, full text in Chinese: http://business.sohu.com/20130402/n371564940.shtml . WARNING: Automatic translation.]
Apr. 02, 2013 20:20
Source: Sohu Finance
Source: Jiangsu Health Department
Jiangsu Province, found four cases of human infection with the H7N9 avian influenza
Provincial Health Department to make every effort to implement five measures epidemic prevention work
Jiangsu Provincial Health Department Bulletin, April 2, Jiangsu Province, diagnosed four cases of human infection with the H7N9 avian influenza.
Patients Xu, female, 45 years old, Jiangning District, engaged in live poultry slaughter. March 19, fever, dizziness, body aches, fatigue and other symptoms.
In the morning of March 27, go to Nanjing sicker ICU treatment in a hospital.
Currently, patients in critical condition, is to rescue.
On the afternoon of March 30, the Jiangsu Provincial Center for Disease testing positive for H7N9 avian influenza virus nucleic acid.
In the afternoon of April 2, review by China CDC influenza center laboratory for the H7N9 avian influenza virus nucleic acid positive.
In accordance with the relevant requirements, the afternoon of April 2, the provincial Health Department organized experts, according to the clinical manifestations, laboratory testing and epidemiological findings, the diagnosis of the cases human infection confirmed cases of the H7N9 avian flu. The patients for the province's first cases of infection with the H7N9 avian flu.
After investigation, the close contacts of the cases of 49 people. Medical observation, so far, all close contacts of the cases were not found to have a fever or respiratory symptoms.
Patients with a mulberry, female, 48 years old, Suqian Shuyang engaged in sheet metal processing. March 19, fever, dizziness, coughing and other symptoms.
March 30, sicker patients transferred to a Nanjing hospital ICU treatment.
Currently, patients in critical condition, is to rescue.
On March 30, the Jiangsu Provincial Center for Disease Detection H7N9 avian influenza virus nucleic acid weakly positive.
In the afternoon of April 2, review by China CDC influenza center laboratory for the H7N9 avian influenza virus nucleic acid positive.
In accordance with the relevant requirements, the afternoon of April 2, the provincial Health Department organized experts, according to the clinical manifestations, laboratory testing and epidemiological findings, the diagnosis of the cases human infection confirmed cases of the H7N9 avian flu.
After investigation, the close contacts of the cases of a total of 60 people. Medical observation, until now, were not found to have a fever or respiratory symptoms.
Patients Shen, male, 83 years old, Suzhou Wujiang District. March 20 fever, cough, sputum production, accompanied by symptoms such as chest tightness, shortness of breath and chest pain.
March 29, sicker patients, treatment to a hospital in Wujiang. Currently, patients in critical condition, is to rescue.
On April 1, the Jiangsu Provincial Center for Disease Detection identified as the H7N9 avian influenza virus nucleic acid positive.
In accordance with the relevant requirements, the afternoon of April 2, the provincial Health Department organized experts, according to the clinical manifestations, laboratory testing and epidemiological findings, the diagnosis of the cases human infection confirmed cases of the H7N9 avian flu.
After investigation, the close contacts of the cases of a total of 15 people. Medical observation, until now, were not found to have a fever or respiratory symptoms.
Patients Zhang, female, 32 years old, Changzhou, now lives in Wuxi city, unemployed.
March 21, fever, cough, and other symptoms. On March 28, the sicker patients transferred to a hospital in Wuxi ICU treatment.
Currently, patients in critical condition, is to rescue.
March 31, identified as the H7N9 avian influenza virus nucleic acid positive by the Jiangsu Provincial Center for Disease Detection.
In accordance with the relevant requirements, the afternoon of April 2, the provincial Health Department organized experts, according to the clinical manifestations, laboratory testing and epidemiological findings, the diagnosis of the cases human infection confirmed cases of the H7N9 avian flu.
After investigation, the close contacts of the cases of a total of 43 people. Medical observation, until now, were not found to have a fever or respiratory symptoms.
After the outbreak, the provincial government attaches great importance to the health sector in accordance with the relevant plans and programs to rapidly launch epidemic prevention and control work.
First, the Provincial Health Department established human infection with the H7N9 avian flu prevention and control work leading group, and people infected with the H7N9 bird flu prevention and control of the Group of Experts, medical treatment expert group issued "effectively strengthen human infection with the H7N9 avian flu prevention and control work urgent notice "to strengthen epidemic prevention and control, and to treat the patient.
The specified 16 tertiary hospitals as a province first admitted to the hospital to make every effort, in accordance with the principle of "concentrated heavy suffering, a pool of experts, pooling of resources, centralized treatment, medical treatment, efforts to reduce the mortality.
Third, the development of Jiangsu Province, people infected with H7N9 avian influenza monitoring the investigation and management solutions, organization of medical and health institutions at all levels to strengthen the monitoring of the unexplained cases of pneumonia and influenza-like illness, active search, and strive to early discovery, early reporting, early diagnosis, early isolation and early treatment.
The fourth is to strengthen the hospital infection control hospital infection prevention and control, strict implementation of disinfection and isolation system and norms, strict precautions against the spread of the epidemic hospital. The fifth is to strengthen the communication links with the departments of agriculture, industry and commerce, business and work together to epidemic prevention and control work.
Currently, no epidemiological association exists between the above four cases.
The experts have warned that the face of human infection with the H7N9 avian flu, Mo panic, to be alert to.
First, to maintain good personal hygiene, such as washing hands frequently, indoor Qin ventilation.
The second is to pay attention to improve nutrition, enhance personal physical.
The third is to avoid contact and edible disease (dead), poultry, livestock.
The event of fever, cough and other symptoms of acute respiratory infections, especially high fever, breathing difficulties, you should seek immediate medical attention.
Provincial Health Department will continue to make every effort to epidemic prevention and control work, and take effective measures to effectively protect public health.
The bio-pharmaceutical stocks today rose (with shares)
The concept of biological vaccines today afternoon again climbing far, Lukang Pharmaceutical daily limit, Neptunus Bioengineering, Rhine biological rose more than 8%, the Central Pharmaceutical Joint rose nearly 6%. Up to now, the daily limit of Lukang Pharmaceutical Neptunus Bioengineering, Rhine biological rose more than 8%, the Central Pharmaceutical Joint rose nearly 6%.
Official sources said recently, Shanghai and Anhui found three cases of human infection with the H7N9 avian influenza, of which two cases had died. The H7N9 subtype of avian influenza was first discovered human infection case, despite the health department admitted that the current understanding of the source of infection of the disease, the spread mechanism and specific treatment are very limited, still unable to stop a flow of five stocks teamed daily limit yesterday.
Pharmaceutical analysts said, more of a stream stocks unworthy of the name to see the possibility of funding short-term speculation, according to past experience. Drugs of some enterprises may be the new found effective influenza, the subsequent effect remains to be seen and repeated verification.
Flu stocks "incoming"
National Health and Family Planning Commission, Bulletin, March 31, Shanghai and Anhui Province, found three cases of human infection with the H7N9 avian influenza, two of whom have died trying to rescue one cases of the Anhui patients with serious illness. H7N9 avian influenza virus previously found only in poultry between never found human infection.
Influenza is an acute respiratory infections caused by influenza viruses, pathogens, three types of influenza virus A, B, C (A, B, C). The influenza virus can infect humans and a variety of animals, is a major pathogen of human influenza, easy variation. Influenza virus according to the H and N antigens divided into many subtypes, H5, H7 and H9 subtype most harmful to birds, and since the 20th century, there are three kinds of influenza A virus (H1N1, H2N2, H3N2) caused 4 influenza pandemic.
According to the original released by the Ministry of Health influenza diagnostic and treatment guidelines (2011) "(hereinafter referred to as" Guidelines "), drug administration, Western medicine is mainly recommended use of neuraminidase inhibitors, the mechanism of action is to prevent the virus from infected cells release and invasion of neighboring cells to reduce the replication of the virus in the body, with activity A, influenza B.
There are two varieties listed in our country, namely Oseltamivir (Oseltamivir) and zanamivir (Zanamivir is), in Japan and other countries have been approved intravenous use Pago zanamivir (Peramivir) and that Ninamiwei of (Laninamivir ) in China is still not listed.
Oseltamivir Roche R & D of Tamiflu in the country is still in a period of patent protection. Shanghai Pharmaceutical (601607) and Guangdong East Sunshine Group is one of only two domestic Roche authorized corporate production and sales of Tamiflu. Hisun Pharmaceutical (600,267) in 2010 was approved by NDRC production of Tamiflu intermediates, but did not obtain Roche authorize production and sales of Tamiflu.
Relenza zanamivir namely Sanofi research and development. The Simcere listed on Nasdaq in 2010, former State Food and Drug Administration approved the production and sale of zanamivir. The Hunan Nonferrous investment and development Pa zanamivir in the country, only listed in Hong Kong, is currently in the stage awaiting approval listing.
Chinese medicine, the Guide emphasizes symptomatic and treatment, medication, against the wind, cold, heat, poison and other features related to Shufeng detoxification capsules class of Yinqiaojiedu, Shuanghuanglian oral formulations, nine the taste Notopterygium particles, and cold antipyretic the oral solution, Lianhuaqingwen capsule, Lotus Qingre effervescent tablets, pediatric Soy Alice heat particles such as proprietary Chinese medicines. Too Dragon Pharmaceutical (600222), Guangzhou Pharmaceutical (600332) the Yiling Pharmaceutical (002603), Zhong Xin Pharmaceutical (600,329), and other related products.
In addition to the drug treatment, the the vaccine preventive effect can not be ignored. The Guide emphasizes influenza vaccination is the most effective means of preventing influenza and its complications can not be replaced by other methods. Currently mainly second generation influenza virus vaccine, batch release in 2010 accounted for 96% of Major manufacturers including Hualan (002 007) shares in Health (Changchun and Shanghai are), Changchun Changsheng, Sanofi, Dalian Ya Lifeng (Fosun Pharmaceutical (600196) Holdings), GSK, Beijing Sinovac (NASDAQ NASDAQ listed), Zhejiang Tianyuan (Novartis subsidiary), 2011 share as shown below. Although many companies influenza vaccine production, but taking into account the vaccination rate is very low, the market potential is greater. (21st Century Business Herald)
H7N9 related to the mask field
The concept of speculation began of H7N9 avian flu from the vaccine, antiviral concept be extended to the field of medical masks, the afternoon of the 2nd, the the main textile Shenda shares first daily limit, leading shares three jeanswest, a new field of textile, Tianshan Textile have rose.
Attachment: masks class enterprise Profile
Leading shares (600,630): Conch Group and its Three Gun Group is the production of anti-SARS masks specified by the Shanghai Municipal Government enterprises, companies use the chitin technology introduced antibacterial functional shirt developed anti-SARS "Qiding antibacterial sanitary mask better antibacterial properties than ordinary sanitary mask, and joint research and development of medical isolation clothing and masks guide wet material and Donghua University, the launch of a series of anti-swine flu products, bring huge social benefits and economic benefits.
Selen Science & Technology (002341): a wholly-owned subsidiary, Suzhou New Lun was the Medical Device Registration Certificate issued by the Food and Drug Administration of Jiangsu Province, Suzhou New Lun production of ordinary surgical masks have been through the review, in line with the market access of medical products The regulations permit registration; issuing time of the February 28, 2013; valid for four years.
TEDA shares (000652): Tianjin TEDA is the largest the masks filter cloth manufacturers, is in line with the United States the only country able to produce N95 grade and Europe P1 and P2 level standard masks cloth manufacturers.
Changshan shares (000158): Chinese textile industry pacesetter companies, the company's main products series and drift of three fabric of cotton, polyester cotton, chemical fiber, color, flower products. And the company also has successfully developed a natural colored cotton, anti-ultraviolet, far-infrared yarn, elastic core yarn, cloth and other products, including natural colored cotton, anti-UV products more features, more in line with medical textiles focus less toxic , insurance requirements, and is ideal for medical prevention product raw materials.
The Shenda shares (600,626): The company is the leading enterprises in the textile industry in Shanghai, Main yarn fabrics, all kinds of textiles, clothing, of reproductions and technology export, needed for the production of raw and auxiliary materials.
Chunhui shares (000,976): The country's largest production base of polyester filament, also the country's textile industry one of the leading enterprises, the annual output of 120,000 tons of polyester filament, occupy a considerable market share in polyester filament in the southern China market share more than 80%. Recent stock continuous active secondary market, due to the production of masks, benefit from a stream.
-
------
[Source: Business Sohu, full text in Chinese: http://business.sohu.com/20130402/n371564940.shtml . WARNING: Automatic translation.]
Apr. 02, 2013 20:20
Source: Sohu Finance
Source: Jiangsu Health Department
Jiangsu Province, found four cases of human infection with the H7N9 avian influenza
Provincial Health Department to make every effort to implement five measures epidemic prevention work
Jiangsu Provincial Health Department Bulletin, April 2, Jiangsu Province, diagnosed four cases of human infection with the H7N9 avian influenza.
Patients Xu, female, 45 years old, Jiangning District, engaged in live poultry slaughter. March 19, fever, dizziness, body aches, fatigue and other symptoms.
In the morning of March 27, go to Nanjing sicker ICU treatment in a hospital.
Currently, patients in critical condition, is to rescue.
On the afternoon of March 30, the Jiangsu Provincial Center for Disease testing positive for H7N9 avian influenza virus nucleic acid.
In the afternoon of April 2, review by China CDC influenza center laboratory for the H7N9 avian influenza virus nucleic acid positive.
In accordance with the relevant requirements, the afternoon of April 2, the provincial Health Department organized experts, according to the clinical manifestations, laboratory testing and epidemiological findings, the diagnosis of the cases human infection confirmed cases of the H7N9 avian flu. The patients for the province's first cases of infection with the H7N9 avian flu.
After investigation, the close contacts of the cases of 49 people. Medical observation, so far, all close contacts of the cases were not found to have a fever or respiratory symptoms.
Patients with a mulberry, female, 48 years old, Suqian Shuyang engaged in sheet metal processing. March 19, fever, dizziness, coughing and other symptoms.
March 30, sicker patients transferred to a Nanjing hospital ICU treatment.
Currently, patients in critical condition, is to rescue.
On March 30, the Jiangsu Provincial Center for Disease Detection H7N9 avian influenza virus nucleic acid weakly positive.
In the afternoon of April 2, review by China CDC influenza center laboratory for the H7N9 avian influenza virus nucleic acid positive.
In accordance with the relevant requirements, the afternoon of April 2, the provincial Health Department organized experts, according to the clinical manifestations, laboratory testing and epidemiological findings, the diagnosis of the cases human infection confirmed cases of the H7N9 avian flu.
After investigation, the close contacts of the cases of a total of 60 people. Medical observation, until now, were not found to have a fever or respiratory symptoms.
Patients Shen, male, 83 years old, Suzhou Wujiang District. March 20 fever, cough, sputum production, accompanied by symptoms such as chest tightness, shortness of breath and chest pain.
March 29, sicker patients, treatment to a hospital in Wujiang. Currently, patients in critical condition, is to rescue.
On April 1, the Jiangsu Provincial Center for Disease Detection identified as the H7N9 avian influenza virus nucleic acid positive.
In accordance with the relevant requirements, the afternoon of April 2, the provincial Health Department organized experts, according to the clinical manifestations, laboratory testing and epidemiological findings, the diagnosis of the cases human infection confirmed cases of the H7N9 avian flu.
After investigation, the close contacts of the cases of a total of 15 people. Medical observation, until now, were not found to have a fever or respiratory symptoms.
Patients Zhang, female, 32 years old, Changzhou, now lives in Wuxi city, unemployed.
March 21, fever, cough, and other symptoms. On March 28, the sicker patients transferred to a hospital in Wuxi ICU treatment.
Currently, patients in critical condition, is to rescue.
March 31, identified as the H7N9 avian influenza virus nucleic acid positive by the Jiangsu Provincial Center for Disease Detection.
In accordance with the relevant requirements, the afternoon of April 2, the provincial Health Department organized experts, according to the clinical manifestations, laboratory testing and epidemiological findings, the diagnosis of the cases human infection confirmed cases of the H7N9 avian flu.
After investigation, the close contacts of the cases of a total of 43 people. Medical observation, until now, were not found to have a fever or respiratory symptoms.
After the outbreak, the provincial government attaches great importance to the health sector in accordance with the relevant plans and programs to rapidly launch epidemic prevention and control work.
First, the Provincial Health Department established human infection with the H7N9 avian flu prevention and control work leading group, and people infected with the H7N9 bird flu prevention and control of the Group of Experts, medical treatment expert group issued "effectively strengthen human infection with the H7N9 avian flu prevention and control work urgent notice "to strengthen epidemic prevention and control, and to treat the patient.
The specified 16 tertiary hospitals as a province first admitted to the hospital to make every effort, in accordance with the principle of "concentrated heavy suffering, a pool of experts, pooling of resources, centralized treatment, medical treatment, efforts to reduce the mortality.
Third, the development of Jiangsu Province, people infected with H7N9 avian influenza monitoring the investigation and management solutions, organization of medical and health institutions at all levels to strengthen the monitoring of the unexplained cases of pneumonia and influenza-like illness, active search, and strive to early discovery, early reporting, early diagnosis, early isolation and early treatment.
The fourth is to strengthen the hospital infection control hospital infection prevention and control, strict implementation of disinfection and isolation system and norms, strict precautions against the spread of the epidemic hospital. The fifth is to strengthen the communication links with the departments of agriculture, industry and commerce, business and work together to epidemic prevention and control work.
Currently, no epidemiological association exists between the above four cases.
The experts have warned that the face of human infection with the H7N9 avian flu, Mo panic, to be alert to.
First, to maintain good personal hygiene, such as washing hands frequently, indoor Qin ventilation.
The second is to pay attention to improve nutrition, enhance personal physical.
The third is to avoid contact and edible disease (dead), poultry, livestock.
The event of fever, cough and other symptoms of acute respiratory infections, especially high fever, breathing difficulties, you should seek immediate medical attention.
Provincial Health Department will continue to make every effort to epidemic prevention and control work, and take effective measures to effectively protect public health.
The bio-pharmaceutical stocks today rose (with shares)
The concept of biological vaccines today afternoon again climbing far, Lukang Pharmaceutical daily limit, Neptunus Bioengineering, Rhine biological rose more than 8%, the Central Pharmaceutical Joint rose nearly 6%. Up to now, the daily limit of Lukang Pharmaceutical Neptunus Bioengineering, Rhine biological rose more than 8%, the Central Pharmaceutical Joint rose nearly 6%.
Official sources said recently, Shanghai and Anhui found three cases of human infection with the H7N9 avian influenza, of which two cases had died. The H7N9 subtype of avian influenza was first discovered human infection case, despite the health department admitted that the current understanding of the source of infection of the disease, the spread mechanism and specific treatment are very limited, still unable to stop a flow of five stocks teamed daily limit yesterday.
Pharmaceutical analysts said, more of a stream stocks unworthy of the name to see the possibility of funding short-term speculation, according to past experience. Drugs of some enterprises may be the new found effective influenza, the subsequent effect remains to be seen and repeated verification.
Flu stocks "incoming"
National Health and Family Planning Commission, Bulletin, March 31, Shanghai and Anhui Province, found three cases of human infection with the H7N9 avian influenza, two of whom have died trying to rescue one cases of the Anhui patients with serious illness. H7N9 avian influenza virus previously found only in poultry between never found human infection.
Influenza is an acute respiratory infections caused by influenza viruses, pathogens, three types of influenza virus A, B, C (A, B, C). The influenza virus can infect humans and a variety of animals, is a major pathogen of human influenza, easy variation. Influenza virus according to the H and N antigens divided into many subtypes, H5, H7 and H9 subtype most harmful to birds, and since the 20th century, there are three kinds of influenza A virus (H1N1, H2N2, H3N2) caused 4 influenza pandemic.
According to the original released by the Ministry of Health influenza diagnostic and treatment guidelines (2011) "(hereinafter referred to as" Guidelines "), drug administration, Western medicine is mainly recommended use of neuraminidase inhibitors, the mechanism of action is to prevent the virus from infected cells release and invasion of neighboring cells to reduce the replication of the virus in the body, with activity A, influenza B.
There are two varieties listed in our country, namely Oseltamivir (Oseltamivir) and zanamivir (Zanamivir is), in Japan and other countries have been approved intravenous use Pago zanamivir (Peramivir) and that Ninamiwei of (Laninamivir ) in China is still not listed.
Oseltamivir Roche R & D of Tamiflu in the country is still in a period of patent protection. Shanghai Pharmaceutical (601607) and Guangdong East Sunshine Group is one of only two domestic Roche authorized corporate production and sales of Tamiflu. Hisun Pharmaceutical (600,267) in 2010 was approved by NDRC production of Tamiflu intermediates, but did not obtain Roche authorize production and sales of Tamiflu.
Relenza zanamivir namely Sanofi research and development. The Simcere listed on Nasdaq in 2010, former State Food and Drug Administration approved the production and sale of zanamivir. The Hunan Nonferrous investment and development Pa zanamivir in the country, only listed in Hong Kong, is currently in the stage awaiting approval listing.
Chinese medicine, the Guide emphasizes symptomatic and treatment, medication, against the wind, cold, heat, poison and other features related to Shufeng detoxification capsules class of Yinqiaojiedu, Shuanghuanglian oral formulations, nine the taste Notopterygium particles, and cold antipyretic the oral solution, Lianhuaqingwen capsule, Lotus Qingre effervescent tablets, pediatric Soy Alice heat particles such as proprietary Chinese medicines. Too Dragon Pharmaceutical (600222), Guangzhou Pharmaceutical (600332) the Yiling Pharmaceutical (002603), Zhong Xin Pharmaceutical (600,329), and other related products.
In addition to the drug treatment, the the vaccine preventive effect can not be ignored. The Guide emphasizes influenza vaccination is the most effective means of preventing influenza and its complications can not be replaced by other methods. Currently mainly second generation influenza virus vaccine, batch release in 2010 accounted for 96% of Major manufacturers including Hualan (002 007) shares in Health (Changchun and Shanghai are), Changchun Changsheng, Sanofi, Dalian Ya Lifeng (Fosun Pharmaceutical (600196) Holdings), GSK, Beijing Sinovac (NASDAQ NASDAQ listed), Zhejiang Tianyuan (Novartis subsidiary), 2011 share as shown below. Although many companies influenza vaccine production, but taking into account the vaccination rate is very low, the market potential is greater. (21st Century Business Herald)
H7N9 related to the mask field
The concept of speculation began of H7N9 avian flu from the vaccine, antiviral concept be extended to the field of medical masks, the afternoon of the 2nd, the the main textile Shenda shares first daily limit, leading shares three jeanswest, a new field of textile, Tianshan Textile have rose.
Attachment: masks class enterprise Profile
Leading shares (600,630): Conch Group and its Three Gun Group is the production of anti-SARS masks specified by the Shanghai Municipal Government enterprises, companies use the chitin technology introduced antibacterial functional shirt developed anti-SARS "Qiding antibacterial sanitary mask better antibacterial properties than ordinary sanitary mask, and joint research and development of medical isolation clothing and masks guide wet material and Donghua University, the launch of a series of anti-swine flu products, bring huge social benefits and economic benefits.
Selen Science & Technology (002341): a wholly-owned subsidiary, Suzhou New Lun was the Medical Device Registration Certificate issued by the Food and Drug Administration of Jiangsu Province, Suzhou New Lun production of ordinary surgical masks have been through the review, in line with the market access of medical products The regulations permit registration; issuing time of the February 28, 2013; valid for four years.
TEDA shares (000652): Tianjin TEDA is the largest the masks filter cloth manufacturers, is in line with the United States the only country able to produce N95 grade and Europe P1 and P2 level standard masks cloth manufacturers.
Changshan shares (000158): Chinese textile industry pacesetter companies, the company's main products series and drift of three fabric of cotton, polyester cotton, chemical fiber, color, flower products. And the company also has successfully developed a natural colored cotton, anti-ultraviolet, far-infrared yarn, elastic core yarn, cloth and other products, including natural colored cotton, anti-UV products more features, more in line with medical textiles focus less toxic , insurance requirements, and is ideal for medical prevention product raw materials.
The Shenda shares (600,626): The company is the leading enterprises in the textile industry in Shanghai, Main yarn fabrics, all kinds of textiles, clothing, of reproductions and technology export, needed for the production of raw and auxiliary materials.
Chunhui shares (000,976): The country's largest production base of polyester filament, also the country's textile industry one of the leading enterprises, the annual output of 120,000 tons of polyester filament, occupy a considerable market share in polyester filament in the southern China market share more than 80%. Recent stock continuous active secondary market, due to the production of masks, benefit from a stream.
-
------
Comment